about
Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminMetformin monotherapy for type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusMeglitinide analogues for type 2 diabetes mellitusMetformin monotherapy for type 2 diabetes mellitusMeglitinide analogues for type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusPharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agentsPotential medicinal benefits of Cosmos caudatus (Ulam Raja): A scoping reviewPatient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XRWhat's next after metformin? focus on sulphonylurea: add-on or combination therapyUse of metformin in diseases of agingOral Hypoglycemic Agents in pregnancy: An UpdateInsulin use early in the course of type 2 diabetes mellitus: the ORIGIN trialOptimal management of type 2 diabetes in patients with increased risk of hypoglycemiaSafety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitusMetaphosphate in the active site of fructose-1,6-bisphosphataseDiabetes in African AmericansDiabetic cardiomyopathy: signaling defects and therapeutic approachesPhytol/Phytanic acid and insulin resistance: potential role of phytanic acid proven by docking simulation and modulation of biochemical alterationsSynthesis and Evaluation of Novel Triterpene Analogues of Ursolic Acid as Potential Antidiabetic AgentTherapeutic ultrasound reverses peripheral ischemia in type 2 diabetic mice through PI3K-Akt-eNOS pathwayThe management of type 2 diabetic patients with hypoglycaemic agentsLifestyle intervention in obese patients with type 2 diabetes: impact of the patient's educational background.Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data.Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus.Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study.Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses.Comparison of three α-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes.Living Well with Diabetes: a randomized controlled trial of a telephone-delivered intervention for maintenance of weight loss, physical activity and glycaemic control in adults with type 2 diabetes.Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action.Metformin combined with acarbose vs. single medicine in the treatment of type 2 diabetes: A meta-analysisKCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.Mechanisms for food polyphenols to ameliorate insulin resistance and endothelial dysfunction: therapeutic implications for diabetes and its cardiovascular complicationsEvaluation and management of diabetes mellitus.
P2860
Q22250892-82E670AE-BFFB-4C0E-B391-16DA6013BDECQ24187392-85FAC570-3040-4B85-A3E5-E6538852B362Q24235718-7C579C1F-00A4-49B0-B753-1E678565208BQ24240522-EC0C7A4F-9E57-4439-B507-34CA1351024FQ24244739-4AA7149C-3D4E-4268-A457-22830EBF626CQ24245352-DCD69061-0511-4E41-9E0E-0E9B86AB84CDQ24246552-2CF39F7F-B5FA-48AB-B09C-401050088465Q24247885-ABC8CA57-4B7D-44EB-83A9-C05EFE6BDB9CQ24247978-52C8C40D-AF47-497B-B460-E4061755CCE1Q26751138-929F02B0-0634-4BDE-BEA2-4CABFE1D9312Q26765224-FA5062F0-C2A4-4083-9075-72DEAD2E6750Q26766404-719F72E1-0628-426D-89B5-9881BAA8416BQ26786524-7563CE92-09E9-4BA1-95C2-E9AC405DAB33Q26828760-6D25BD6E-BC85-4F32-B4FC-12295787899BQ26851879-2C87DBD5-4CEC-4E86-B318-597731AD54B8Q27024597-B32B0EE9-799F-4921-A9DB-E143690540D5Q27026847-98449C46-A19F-4E7F-982E-14409CD89A42Q27027877-38FD5E46-2DFB-4956-9352-BBF904D06FE1Q27640542-C26FAB1A-EB41-4703-A055-C023FE83871DQ28394087-ABBFAF85-F432-45EC-88F3-844EBB2A9C91Q28395852-2B0F88AF-015E-4A0A-84AC-D95ADD8D2E5DQ28484781-C811F3F6-9FE7-48D3-8625-5EF831CBD965Q28548452-D859C89E-3A8C-45A3-847C-98C34ACCFB4DQ30372593-28AAD179-38F9-42CA-87C6-236C5B206632Q30417363-97EBFD66-94B6-40E7-9D1A-0859DCB8F4E7Q30441090-48FDC16F-53D8-4B6B-9804-E5C14E663098Q31071930-ECF718D8-A367-47FA-9C91-945C1D06000AQ32066328-8E8F83BD-8398-4224-9C5A-41E714C1CC9DQ33447184-314C9D14-833E-4452-95E8-371F103E76A2Q33476850-E434298C-658A-44C8-BB30-D427F1E8EB6BQ33488897-D4D42D09-3464-4700-9C5C-48837139DC65Q33622266-09809B4A-088B-4C93-8480-285D6469B6ACQ33647443-2733E053-1150-4FBD-AF04-F12BE380AFFFQ33664745-99D04D11-0CEF-47C3-9010-43B3725DB515Q33744996-F92FAD82-465D-41BB-9F12-E8EE29B4566FQ33771570-B8566E53-039A-405B-8AF1-2A23A6E64C92Q33804747-893C9AD2-ADBF-4ED3-8553-C0A2BAB37832Q33813015-0739BA9E-5DF4-45BA-AFC0-2C922824FB99Q33816859-A7479D2E-6D5C-47E5-B0F5-C2E9A9E4CF29Q33931988-BDC68D5A-FA61-4937-AACA-9DC4B9174130
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pharmacologic therapy for type 2 diabetes mellitus.
@ast
Pharmacologic therapy for type 2 diabetes mellitus.
@en
type
label
Pharmacologic therapy for type 2 diabetes mellitus.
@ast
Pharmacologic therapy for type 2 diabetes mellitus.
@en
prefLabel
Pharmacologic therapy for type 2 diabetes mellitus.
@ast
Pharmacologic therapy for type 2 diabetes mellitus.
@en
P1476
Pharmacologic therapy for type 2 diabetes mellitus.
@en
P2093
DeFronzo RA
P304
P356
10.7326/0003-4819-131-4-199908170-00008
P407
P577
1999-08-01T00:00:00Z